Cargando…
Nanoantibodies: small molecules, big possibilities
Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645571/ https://www.ncbi.nlm.nih.gov/pubmed/36606147 http://dx.doi.org/10.5114/bta.2021.108724 |
_version_ | 1784826990761607168 |
---|---|
author | Pedreáñez, Adriana Mosquera-Sulbarán, Jesús Muñóz, Nelson Tene, Diego Robalino, Jorge |
author_facet | Pedreáñez, Adriana Mosquera-Sulbarán, Jesús Muñóz, Nelson Tene, Diego Robalino, Jorge |
author_sort | Pedreáñez, Adriana |
collection | PubMed |
description | Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from these antibodies, called as VHH or nanoantibodies (Nbs), have also been described. Since their discovery, Nbs have been widely used in the fields of research, diagnostics, and pharmacotherapy. Despite being approximately one-tenth the size of a conventional antibody, they retain similar specificity and affinity to conventional antibodies and are much easier to clone and manipulate. Their unique properties such as small size, high stability, strong antigen binding affinity, water solubility, and natural origin make them suitable for the development of biopharmaceuticals and nanoreagents. The present review aims to describe the main structural and biochemical characteristics of these antibodies and to provide an update on their applications in research, biotechnology, and medicine. For this purpose, an exhaustive search of the biomedical literature was performed in the following databases: Medline (PubMed), Google Scholar, and ScienceDirect. Meta-analyses, observational studies, review articles, and clinical guidelines were reviewed. Only original articles were considered to assess the quality of the evidence. |
format | Online Article Text |
id | pubmed-9645571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-96455712023-01-04 Nanoantibodies: small molecules, big possibilities Pedreáñez, Adriana Mosquera-Sulbarán, Jesús Muñóz, Nelson Tene, Diego Robalino, Jorge BioTechnologia (Pozn) Reviews Papers Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from these antibodies, called as VHH or nanoantibodies (Nbs), have also been described. Since their discovery, Nbs have been widely used in the fields of research, diagnostics, and pharmacotherapy. Despite being approximately one-tenth the size of a conventional antibody, they retain similar specificity and affinity to conventional antibodies and are much easier to clone and manipulate. Their unique properties such as small size, high stability, strong antigen binding affinity, water solubility, and natural origin make them suitable for the development of biopharmaceuticals and nanoreagents. The present review aims to describe the main structural and biochemical characteristics of these antibodies and to provide an update on their applications in research, biotechnology, and medicine. For this purpose, an exhaustive search of the biomedical literature was performed in the following databases: Medline (PubMed), Google Scholar, and ScienceDirect. Meta-analyses, observational studies, review articles, and clinical guidelines were reviewed. Only original articles were considered to assess the quality of the evidence. Termedia Publishing House 2021-09-30 /pmc/articles/PMC9645571/ /pubmed/36606147 http://dx.doi.org/10.5114/bta.2021.108724 Text en © 2021 Institute of Bioorganic Chemistry, Polish Academy of Sciences https://creativecommons.org/licenses/by-nc-nd/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), allowing third parties to download and share its works but not commercially purposes or to create derivative works. |
spellingShingle | Reviews Papers Pedreáñez, Adriana Mosquera-Sulbarán, Jesús Muñóz, Nelson Tene, Diego Robalino, Jorge Nanoantibodies: small molecules, big possibilities |
title | Nanoantibodies: small molecules, big possibilities |
title_full | Nanoantibodies: small molecules, big possibilities |
title_fullStr | Nanoantibodies: small molecules, big possibilities |
title_full_unstemmed | Nanoantibodies: small molecules, big possibilities |
title_short | Nanoantibodies: small molecules, big possibilities |
title_sort | nanoantibodies: small molecules, big possibilities |
topic | Reviews Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645571/ https://www.ncbi.nlm.nih.gov/pubmed/36606147 http://dx.doi.org/10.5114/bta.2021.108724 |
work_keys_str_mv | AT pedreanezadriana nanoantibodiessmallmoleculesbigpossibilities AT mosquerasulbaranjesus nanoantibodiessmallmoleculesbigpossibilities AT munoznelson nanoantibodiessmallmoleculesbigpossibilities AT tenediego nanoantibodiessmallmoleculesbigpossibilities AT robalinojorge nanoantibodiessmallmoleculesbigpossibilities |